| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Radiation therapy plus osimertinib vs osimertinib alone in epidermal growth factor receptor mutated non-small cell lung cancer: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mubeena Javed, Maham Fatima, Muhammad Bari Hassan, Sanjeet Kumar, Raja Pawan, Vikram Singh, Kheentesh Kumar, Rabia Amir, Ali Karim, Inshal Jawed, Farah Alam, Danaish Kumar, Rahul Rai, Hersh Tilokani and Syed Ali Farhan Abbas Rizvi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Inshal Jawed, Chief Physician, Senior Researcher, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com |
| Key Words |
Brain neoplasms; Carcinoma; Non-small-cell lung; ErbB receptors; Protein kinase inhibitors; Radiotherapy |
| Core Tip |
The appearance of brain metastases in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer makes therapy harder. A review of 27 studies involving 14955 patients shows that osimertinib and other third-generation EGFR tyrosine kinase inhibitors achieve higher activity inside the brain and produce better responses than earlier drugs. Those with multiple brain metastases who are treated with combined radiation therapy and osimertinib do better than those treated with osimertinib alone. Cognitive function is better preserved by stereotactic radiosurgery than whole-brain radiotherapy, all while giving the same good results in managing tumors, backing individualized methods linked to the disease and patient profile. |
| Publish Date |
2026-04-23 11:05 |
| Citation |
Javed M, Fatima M, Hassan MB, Kumar S, Pawan R, Singh V, Kumar K, Amir R, Karim A, Jawed I, Alam F, Kumar D, Rai R, Tilokani H, Rizvi SAFA. Radiation therapy plus osimertinib vs osimertinib alone in epidermal growth factor receptor mutated non-small cell lung cancer: A systematic review. World J Methodol 2026; 16(2): 109986 |
| URL |
https://www.wjgnet.com/2222-0682/full/v16/i2/109986.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v16.i2.109986 |
